Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27696933 | 0.98 | CA1 (0.40) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL29422137 | 0.83 | CA12 (0.41) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL28026126 | 0.83 | CA12 (0.41) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL1609396 | 0.81 | CA12 (0.41) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL20711946 | 0.81 | CA1 (0.41) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL3346353 | 0.81 | CA12 (0.41) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL24191656 | 0.80 | DGAT1 (0.41) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL1927273 | 0.79 | DGAT1 (0.41) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL6899867 | 0.79 | CA1 (0.43) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL1949138 | 0.79 | DGAT1 (0.41) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207561-A | The prodrug of 17 β HSD1-inhibitor | 佛恩多制药有限公司 | 2017-09-26 | — | — | CN | claimed |
| CN-105518017-A | Therapeutically active estratriene thiazole derivatives as 17 beta-hydroxysteroid dehydrogenase type 1 inhibitors | FORENDO PHARMA LTD | 2016-04-20 | — | — | CN | claimed |
| CN-105518016-A | Therapeutically active estratriene thiazole derivatives as 17 beta-hydroxysteroid dehydrogenase type 1 inhibitors | FORENDO PHARMA LTD | 2016-04-20 | — | — | CN | claimed |
| CN-102675226-B | 3-substituted-1-methyl-quinazoline-2,4-dione compounds, preparation method and application thereof | UNIV SOUTHWEST | 2014-04-23 | — | — | CN | claimed |
| CN-102675226-A | 3-substituted-1-methyl-quinazoline-2,4-dione compounds, preparation method and application thereof | UNIV SOUTHWEST | 2012-09-19 | — | — | CN | claimed |
| EP-4540230-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250026731-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | EMPATHBIO INC (US) | 2025-01-23 | — | — | US | disclosed |
| US-20240246950-A1 | Anilino-Pyrazole Derivatives, Compositions and Methods Thereof | Ensem Therapeutics (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2024065107-A9 | NOVEL COMPOSITIONS COMPRISING TERPENOID AND MACROMOLECULE, AND USES THEREOF | POWIN BIOMEDICAL CO., LTD. (CN) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024065107-A1 | NOVEL COMPOSITIONS COMPRISING TERPENOID AND MACROMOLECULE, AND USES THEREOF | POWIN BIOMEDICAL CO., LTD. (CN) | 2024-04-04 | — | — | WO | disclosed |
| CN-117769443-A | Fibroblast activation protein inhibitor and use thereof | 3B制药有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023244710-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| CN-1211991-A | Compounds with growth hormone releasing properties | NOVO NORDISK AS (DK) | 1999-03-24 | — | — | CN | disclosed |
| WO-1999003484-A1 | THERAPEUTIC HEMOGLOBIN COMPOSITION HAVING ISOTROPICALLY INCREASED SIZE | BAXTER INTERNATIONAL INC. (US) | 1999-01-28 | — | — | WO | disclosed |
| US-5155130-A | Lipoxygenase inhibitors | CIBA-GEIGY CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
| US-5077432-A | Monobactam hydrazides containing catechol sulfonic acid groups | E. R. SQUIBB & SONS, INC. (US) | 1991-12-31 | — | — | US | disclosed |
| EP-0438752-A1 | Monobactam hydrazides containing catechol sulfonic acid groups | E.R. SQUIBB & SONS, INC. (US) | 1991-07-31 | — | — | EP | disclosed |
| US-5030724-A | Monobactam hydrazides containing catechol sulfonic acid groups | E. R. SQUIBB & SONS, INC. (US) | 1991-07-09 | — | — | US | disclosed |
| EP-0412939-A2 | Certain benzopyran and benzothiopyran derivatives | CIBA-GEIGY AG (CH) | 1991-02-13 | — | — | EP | disclosed |
| EP-0183584-B1 | ESTERS OF DERIVATIVES OF 2-ALPHA-HYDROXY-SUBSTITUTED 4-HYDROXY-3-QUINOLINE CARBOXYLIC ACID, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246950-A1 | Anilino-Pyrazole Derivatives, Compositions and Methods Thereof | CDK2, CDK3, CDK4 | CA12 4341/4885CA1 4122/4885CA2 2628/4885 |
| US-20250026731-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | COMT, PNMT, ABCB1 | CA12 4196/4885CA1 3628/4885CA2 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.